Peptides vs. Diet and Cardio for Fat Loss: The Evidence

Energy balance sets the limits

Fat loss still comes down to energy balance: you lose fat when you take in less energy than you use. Every approach on this page works inside that rule. Diet and exercise change the numbers directly. The peptides discussed here try to change the signals around a deficit instead, either by curbing appetite or by raising growth hormone, which helps break down stored fat.

What separates them is the amount of human evidence behind each one. GLP-1 drugs have large randomized trials. Growth hormone secretagogues and growth hormone fragments mostly have a plausible mechanism and user reports, with little or no trial data on fat loss. This page compares them on that basis, as of October 2026.

How the options compare

GLP-1 drugs: the only group with large trials

Semaglutide (Wegovy, Ozempic) is a GLP-1 receptor agonist. Tirzepatide (Zepbound, Mounjaro) acts on both the GLP-1 and GIP receptors. Both increase satiety and slow gastric emptying, so people eat less without fighting hunger as hard.

In the STEP 1 trial, 1,961 adults with overweight or obesity took semaglutide 2.4 mg weekly or placebo, both alongside lifestyle counseling. After 68 weeks, average weight loss was 14.9% with semaglutide and 2.4% with placebo. In SURMOUNT-5, a head-to-head trial of 751 adults with obesity, tirzepatide (10 or 15 mg weekly) produced 20.2% average weight loss at 72 weeks, compared with 13.7% for semaglutide (1.7 or 2.4 mg). SURMOUNT-5 was open-label and funded by Eli Lilly, which makes tirzepatide.

Two approvals have changed the semaglutide picture:

• Oral Wegovy. FDA approved a once-daily 25 mg semaglutide tablet for weight management on December 22, 2025. In the 64-week OASIS 4 trial of 307 adults, average weight loss was 13.6% counting everyone randomized, or 16.6% if everyone had stayed on treatment, versus 2.4% (or 2.7%) on placebo.
• Wegovy HD (7.2 mg). FDA approved a 7.2 mg weekly injection on March 19, 2026. In the 72-week STEP UP trial, average weight loss was 18.8% on 7.2 mg, 15.5% on 2.4 mg and 3.9% on placebo. The label reports altered skin sensation (dysesthesia) in 22% of people on 7.2 mg.

Trial and label doses follow fixed titration schedules. Per the Wegovy label, injectable semaglutide starts at 0.25 mg weekly and steps up every four weeks to a 1.7 or 2.4 mg maintenance dose. Per the Zepbound label, tirzepatide starts at 2.5 mg weekly and rises in 2.5 mg steps, at least four weeks apart, to a maintenance dose of 5, 10 or 15 mg. The low starting doses are there to limit nausea while the body adjusts; they aren't the doses that produced the trial results. The most common side effects are gastrointestinal (nausea, diarrhea, vomiting, constipation), and both labels carry a boxed warning about thyroid C-cell tumors based on rodent studies.

What happens to muscle

Weight loss on this scale takes some lean mass with it. A 2024 review in Diabetes, Obesity and Metabolism found that lean mass made up anywhere from about 15% or less to 40-60% of total weight lost across GLP-1 trials. The authors point out that "lean mass" includes organs, bone and water, not only muscle, and that MRI studies suggest muscle loss is roughly what you'd expect for the amount of weight lost. They name older age and more severe disease as reasons for extra caution, because of the risk of sarcopenia (age-related muscle loss).

A small MRI analysis of STEP UP (55 participants, most on 7.2 mg) found a large drop in fat volume and a smaller drop in thigh muscle volume that wasn't statistically significant. Fat inside the muscle went down, and sit-to-stand performance held steady. Lifters commonly pair GLP-1 drugs with high protein intake and continued resistance training to protect muscle; we didn't find a GLP-1 trial that tested how much that helps.

Gray-market versions

As of October 2026, FDA says it has warned companies selling semaglutide, tirzepatide and retatrutide labeled "for research purposes" or "not for human consumption," and it urges consumers not to buy them. FDA had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026. Neither drug is named on WADA's 2026 Prohibited List.

Growth hormone secretagogues: a sound mechanism, no fat-loss trials

CJC-1295 is a GHRH analog, and ipamorelin is a GH secretagogue that acts on the ghrelin receptor. Users commonly stack the two to raise the body's own growth hormone release. The fat-loss argument rests on growth hormone itself: GH drives lipolysis in fat cells, and a 2011 review notes that recombinant GH reduces fat mass in adults with GH deficiency, with larger doses producing larger reductions.

The closest human evidence for this route is tesamorelin, an FDA-approved GHRH analog. In a 2007 trial of 412 people with HIV and excess abdominal fat, 2 mg daily for 26 weeks reduced visceral adipose tissue (VAT) by 15.2%, while it rose 5.0% on placebo. IGF-1 rose 81%. That's a specific medical population and a different molecule, so it shows the GHRH pathway can shrink belly fat in people. It doesn't show that CJC-1295 does the same in a lean athlete.

For CJC-1295 and ipamorelin themselves, the record is thin:

• CJC-1295. In 2006 studies in healthy adults, a single subcutaneous injection raised GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9-11 days. Those studies didn't measure body composition. FDA's December 2024 review for its compounding advisory committee found no evidence of effectiveness for any condition it considered. A Phase 2 trial in HIV lipodystrophy was reportedly stopped after a participant had a fatal heart attack; the attending physician blamed underlying coronary disease, and the data were never published. In the 2006 studies, about 70% of participants had injection-site reactions after a single dose, and headache, diarrhea and flushing also occurred.
• Ipamorelin. Human data are limited, which is why the site rates the evidence as moderate: one IV dosing study in 48 healthy men and a Phase 2 trial in 117 adults recovering from abdominal surgery. That trial missed its primary endpoint (median 25.3 versus 32.6 hours to a tolerated meal, not statistically significant), and development stopped. Neither study measured fat. At FDA's October 2024 advisory meeting, a speaker representing a compounding pharmacy said clinicians use ipamorelin to raise lean mass and lower body fat, citing clinician feedback and a review of secretagogues as a class rather than an ipamorelin trial. The committee voted 0-12, with one abstention, against letting pharmacies compound ipamorelin free base.

Community protocols usually pair ipamorelin with Mod GRF 1-29 (CJC-1295 without DAC), with users commonly reporting 100-300 mcg of each, often at bedtime. These are user reports, not tested doses. Users describe flushing, water retention, numb or tingling hands and changes in sleep. Reported fat-loss results vary, and they're hard to separate from the diet and training that come with them. Both compounds are prohibited at all times under section S2.2.4 of WADA's 2026 list. For the IGF-1 questions that come with long-term use, see our overview of long-term health effects of peptide use.

Growth hormone fragments: AOD-9604 and hGH 176-191

AOD-9604 is a modified piece of the growth hormone molecule, closely related to the fragment sold as hGH 176-191. The idea was to keep GH's effect on fat without its effects on growth or blood sugar.

The human trials didn't bear that out. According to FDA's 2024 briefing document, all of the human data come from oral or intravenous AOD-9604, and most studies found no weight-loss benefit over placebo. The largest, the OPTIONS trial, enrolled 536 adults with obesity on oral doses of 0.25, 0.5 or 1 mg daily for 24 weeks alongside a supervised diet and exercise program. It found no significant difference from placebo at 12 weeks, and the developer ended work on AOD-9604 for obesity in February 2007. A company-funded 2013 summary of six trials reported tolerability similar to placebo. FDA found no human data at all for subcutaneous or transdermal use, which is how it's sold today.

Users commonly report injecting about 300 mcg a day subcutaneously, a route and dose no human trial has tested. Forum reports of fat loss are mostly underwhelming, which fits the trial record. For hGH 176-191, our PubMed search found no human weight-loss trials. Both fragments are prohibited under section S2.2.3 of WADA's 2026 list.

Diet and exercise as the baseline

The placebo groups in the GLP-1 trials weren't untreated: they got diet and exercise counseling and lost 2-4% of body weight over 64-72 weeks. That's the closest thing to a controlled "diet and cardio" arm in this research. Those trials enrolled people with overweight or obesity, though, not lean, trained athletes, so the numbers don't predict what a disciplined cut achieves.

The practical difference is hunger. A deficit run on willpower works, but appetite often pushes back as the weeks go on, and GLP-1 drugs blunt that pushback. For how these compounds get combined, see our article on fat-loss peptide stacks, and for the muscle side, peptides and muscle hypertrophy.

Matching the tool to the problem

• Hunger is the main obstacle and there's a lot of weight to lose. GLP-1 drugs have by far the strongest evidence, as prescription medicines used under medical supervision.
• A lean lifter wants to keep muscle while cutting. The case for GH secretagogues rests on mechanism, a related drug tested in a different population, and user reports. No trial has measured whether CJC-1295 or ipamorelin preserves muscle during a diet.
• Tested athletes. Every peptide on this page except the GLP-1 drugs is prohibited at all times on WADA's 2026 list. Our guide to WADA bans versus the law explains the difference.

What we still don't know

• Whether CJC-1295 or ipamorelin changes body composition in healthy people. As of October 2026, we found no published trial that measured it.
• How much of the lean mass lost on GLP-1 drugs is muscle, and whether high protein intake and resistance training change that meaningfully.
• Whether adding a GH secretagogue to a GLP-1 drug does anything beyond the GLP-1 alone. Some users combine them; we found no study of the combination.